Kintor Pharmaceutical Limited (HKEX: 9939), a China-based clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced on Sunday that it has been included in the MSCI China Index, effective 31 May 2022.

Morgan Stanley Capital International has compiled the MSCI series index, which is claimed to be one of the most influential stock indexes in the world. MSCI revealed the results of the semi-annual review of the MSCI GLOBAL SMALL CAP INDEXES, including Kintor Pharma's inclusion in the China index.

Tong Youzhi, the founder, chairman, and CEO of Kintor Pharma said, 'We are excited to be included in the MSCI China Index as it reflects the recognition of and confidence in our company's business and development prospects from the international capital markets. Kintor expects that the inclusion in the MSCI China Index will facilitate further expansion of our investor base and enhance the liquidity of the company's stock– both of which will have a positive impact on our development. Kintor Pharma will continue to advance its progress in research and development, clinical operations, and our commercialisation efforts to deliver medicines that advance human health.'